Im­mu­nicum's den­drit­ic cell ther­a­py flunks co-pri­ma­ry end­point in 'pos­i­tive' PhII

Im­mu­nicum’s im­mune prim­ing den­drit­ic cell in­jec­tion has missed the mark on a Phase II ex­plorato­ry tri­al in metasta­t­ic kid­ney can­cer, but that’s not stop­ping the com­pa­ny from cast­ing the re­sults in a pos­i­tive light and push­ing the pro­gram in­to late-stage stud­ies.

To hear Im­mu­nicum tell it, the most im­por­tant out­come in the MERE­CA topline re­sults is that 5 out of 45 evalu­able pa­tients re­ceiv­ing il­ix­aden­cel plus Pfiz­er’s ty­ro­sine ki­nase in­hibitor Su­tent achieved com­plete tu­mor re­sponse, an 11% rate com­pared to 4%, or 1 out of 25, for the Su­tent monother­a­py arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER